Merck (Darmstadt, Germany) announced on Wednesday that it has proposed acquiring Versum Materials for $5.9 billion in cash, surpassing the all-stock, $4-billion offer Entegris and Versum announced in January.
Merck says a combination with Versum would create a “deep and complementary portfolio” of electronic materials, equipment and services for the semiconductor and display industries with combined proforma annual performance materials sales of €3.5 billion ($3.98 billion). “The combined R&D capabilities would enable faster innovation cycles and strengthen the product offering to customers,” Merck adds. “They would offer increased scale, product and service depth, an enhanced global presence and a strengthened supply chain, which would help drive leading innovation supported by long-term tailwinds in the industry. Moreover, they would provide an additional source for innovation through leading positions in attractive segments.”
Versum said, however, that it continues to believe in the strategic and financial rationale of the proposed merger of equals with Entegris. “Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, Versum’s Board of Directors will thoroughly review the Merck proposal,” Versum adds.
Merck’s $48/share offer is a 51.7% premium to Versum’s price 25 January 2019, the last trading day prior to Entegris’s announcement, and a 15.9% premium to Versum’s current price. It reflects an enterprise value for Versum 13.3 times 2018 EBITDA multiple.
In a letter to Versum’s board of directors, Merck says Entegris’s offer “significantly” undervalues Versum. “Instead of the speculative value offered by the Entegris transaction, the all-case proposal would deliver immediate and certain cash value to Versum stockholders and employees, shielding them from the significant integration, operational, and market risks posed by the all-stock Entegris transaction,” the letter adds. Stefan Oschmann, Chairman of the Executive Board and CEO of Merck, says the company anticipates €60 million in annual cost synergies to be fully realized by 2022, with the deal closing in the second half of 2019. Entegris and Versum had expected their merger to generate more than $75 million within 12 months of the deal’s close.
Entegris and Versum had expected their merger to generate more than $75 million within 12 months of the deal’s close.
Merck has engaged Guggenheim Securities, LLC as its financial advisor and Sullivan & Cromwell LLP as its legal counsel. Entegris did not immediately respond to requests for comment.
By Rebecca Coons
Source: Chemical Week
LinkedIn Twitter Xing EmailINEOS has postponed work on the propane dehydrogenation (PDH) unit at its Antwerp, Belgium site, opting to prioritise construction of the cracker, a company spokesperson said on […]
TechnipFMC says it has resumed activities related to the previous announced separation of the company into two separate pure-play businesses, TechnipFMC and Technip Energies.
Solvay’s new policy increases maternity leave to 16 weeks. It is now available to any co-parent regardless of gender or sexual orientation; it also includes parents who adopt. The parent employed by Solvay will receive 100% of his or her salary during this leave period.